- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04065737
Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization (STOP)
A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization
Study Overview
Status
Intervention / Treatment
Detailed Description
this study is a non-randomized, phase II, open-label study. Phase II clinical trials test the safety and effectiveness of an investigational drug or combination of drugs to learn whether it works in preventing or treating a disease.
the purpose of this study is to evaluate the effectiveness of sintilimab in preventing the onset of oral cancer in patients with high-risk oral premalignant lesions, who had oral cancer at least once before.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Guopei Zhu
- Phone Number: +8602164175590
- Email: antica@gmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200011
- Shanghai Ninth People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18
- Histological evidence of oral premalignant lesions (such as leukoplakia and/or erythroplakia). A history of invasive oral cancer or oral cancer in situ, which was histologically confirmed.
- With at least on high-risk profiles: a. have LOH at 3p14 and/or 9p21; b. pathologically diagnosis with severe dysplasia; c. size of lesions >200mm².
- Eastern Cooperative Oncology Group Performance Status (ECOG) performance scale: 0-1.
Adequate organ and bone marrow function:
- CBC: absolute neutrophil count (ANC) ≥ 1.5 × 10^9 / L; platelet count (PLT) ≥ 100 × 10^9 / L; hemoglobin content (HGB) ≥ 9.0 g / dL.
- Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.
- Renal function: serum creatinine (Cr) ≤ 1.5 × ULN.
- Female subject of childbearing potential should have a negative urine or serum pregnancy test < 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of study therapy through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses > 1 year.
- Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of the study therapy.
- Voluntarily signed written informed consent form, willing and able to comply with scheduled visits and other requirements of the study.
Exclusion Criteria:
- Should receive subsequent adjuvant therapy (such as radiotherapy, chemotherapy, immunotherapy)
- Received major surgery (such as craniotomy, thoracotomy or laparotomy) within 4 weeks of the first dose of study drugs or open wound, ulcer or fracture.
- Received any anti-tumor therapy (chemotherapy, targeted therapy, tumor immunotherapy or arterial embolization) or radiotherapy within 4 weeks of the first dose of study treatment.
- Prior therapy with anti-PD-1,anti-PD-L1,anti-CTLA4 antibody.
- Currently participating in interventional clinical research treatment, or receiving other research medications within 4 weeks prior to the first dose or used research equipment
- Received any investigational agent within 4 weeks of the first dose of study treatment.
- Received radiotherapy within 4 weeks of the first dose of study treatment. Received systemic treatment with high-dose corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive drugs within 4 weeks of first dose. Inhaled or topical steroids and adrenal replacement steroid are permitted in the absence of active autoimmune disease.
- Received attenuated live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during the study period.
- Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment.
- Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation
- Known allergic or hypersensitive to docetaxel, any monoclonal antibody or any other components used in their preparation.
Uncontrolled concomitant disease, including but not limited to :
- Active or poorly controlled severe infection
- Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)
- Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection
- Active tuberculosis
- Symptomatic congestive heart failure (New York Heart Association grade III-IV) or symptomatic, poorly controlled arrhythmia
- Uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg)
- Prior arterial thromboembolism event, including myocardial infarction, unstable angina, stroke, and transient ischemic attack, within 6 months of enrollment
- Known history of, or any evidence of active, non-infectious pneumonitis.
- Other primary malignancy, with the exception of the skin or squamous cell carcinoma of the skin or in situ cervical cancer.
- Women who are pregnant or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sintilimab
Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: 8cycles (6 months) or randomization to the date of the first documented oral cancer incidence
|
Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells. other name: IBI308
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
oral cancer incidence rate
Time Frame: 2 years
|
The proportion of patients who has been diagnosed with oral cavity cancer
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
clinical response rate of oral premalignant lesions
Time Frame: 2 years
|
The proportion of patients whose oral premalignant lesions experienced a Complete Response or a Partial Response
|
2 years
|
pathologically response rate of oral premalignant lesions
Time Frame: 2 years
|
The proportion of patients whose oral premalignant lesions experienced a locally complete response or decrease of histopathological grade
|
2 years
|
Duration of Response (DoR) of oral premalignant lesions
Time Frame: 2 years
|
the time from the date for first documented response of complete response (CR) or partial response (PR) until the date for the first documented response of progressive disease (PD), incidence of oral cancer or death in the absence of progression.
|
2 years
|
2 year oral-cancer-free survival
Time Frame: 2 years
|
time from randomization to the development of histologically confirmed oral cancer or death of any cause, whichever occurs first
|
2 years
|
Treatment-related Adverse Events (AEs)
Time Frame: From the date of randomization to 90 days after last dose of study treatment
|
The grade of AEs and the number of patients with AEs are assessed by the investigator based on CTCAE v4.0 from the date of randomization to 90 days after last dose of study treatment
|
From the date of randomization to 90 days after last dose of study treatment
|
Overall survival (OS)
Time Frame: 2 year
|
OS (per RECIST 1.1 as assessed by the investigator) is defined as the time from the date of randomisation until death due to any cause.
|
2 year
|
quality of life(QOL)
Time Frame: 2 years
|
EORTC QLQ-C30 questionnaires
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019HNRT01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precancerous Conditions
-
Xiyuan Hospital of China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing Friendship... and other collaboratorsRecruiting
-
National Cancer Institute (NCI)CompletedNeoplasms | Precancerous ConditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Emory UniversityNational Institutes of Health (NIH)CompletedPrecancerous ConditionsUnited States
-
All India Institute of Medical Sciences, New DelhiCompletedPrecancerous ConditionsIndia
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
-
National Cancer Institute (NCI)TerminatedMetaplasia | Dysplasia | Pulmonary Precancerous ConditionUnited States
-
Renmin Hospital of Wuhan UniversityCompleted
-
National Cancer Institute (NCI)CompletedRectal Cancer | Colon Cancer | Precancerous ConditionUnited States
Clinical Trials on Sintilimab
-
Beijing Tiantan HospitalRecruiting
-
RemeGen Co., Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced or Metastatic NSCLCChina
-
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (USA), Inc.WithdrawnMetastatic Cutaneous Melanoma | Unresectable Cutaneous MelanomaUnited States, Germany, France, Australia, Spain, Switzerland, United Kingdom
-
Zhejiang Cancer HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting
-
The First Hospital of Jilin UniversityActive, not recruitingLocally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | TislelizumabChina
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Shanghai YingLi Pharmaceutical Co. Ltd.RecruitingAdvanced Solid TumorsChina
-
Wuhan UniversityRecruitingEsophageal Squamous Cell CarcinomaChina